Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Hologic Inc announces Health Canada approves use of Aptima HPV 16 18/45 Genotype Assay on Hologic's Panther System


Tuesday, 4 Feb 2014 08:01am EST 

Hologic Inc:Says Health Canada approved the Aptima HPV 16 18/45 genotype assay for use on the company's fully automated Panther system.Says Hologic's Aptima HPV 16 18/45 genotype assay is the only approved test for genotyping human papillomavirus (HPV) types 16, 18 and/or 45 in Canada.Says recent data suggests that although cervical cancer incidence has decreased since the 1970s, the prevalence of adenocarcinoma cases has risen about 32 pct in the same time frame.Says detection of HPV types 16, 18 and/or 45 as part of reflex testing may help clinicians identify up to 94 pct of all cervical adenocarcinomas.Says Although HPV genotype 45 is fairly uncommon, identified in only 0.4 percent of women with normal cytology, it is the third most common HPV genotype associated with invasive cancer.Says the addition of HPV genotype 45 is designed to help identify more women at risk for adenocarcinoma, with minimal impact to colposcopy rates.Says Studies have shown that HPV types 16, 18 and 45 are more likely to be integrated into the human genome than are the other HPV types, and tumors with these genotypes may present earlier. 

Company Quote

32.28
-0.285 -0.88%
10:00am EST